Orgotein

Summary

Orgotein (CHEMBL2108545) is an approved unknown (ATC M01AX14); indicated across 1 condition including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: M01AX14
• Indications: 1 condition
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108545
Name	Orgotein
Type	Unknown
Max phase	4
ATC	M01AX14

Also known as: Ontosein, Orgotein, bovine, Orgoteina, Orgoteine, Ormetein, Palosein, Sod, Superoxide dismutase, Superoxide dismutase (bovine), Superoxide dismutase (sod) enzyme, ORGOTEIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	2
Not specified	2
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02753582	PHASE4	UNKNOWN	The Effect of SOD Enzyme on Frailty and HRQOL Among Indonesian Pre-frail Elderly: A Double Blind Randomized Controlled Trial
NCT05711810	PHASE4	COMPLETED	Medicine-induced Cardiac Hemodialysis on COVID-19
NCT00800995	PHASE3	COMPLETED	Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
NCT06319378	PHASE2	RECRUITING	Cancer Related Major Depression Treated With a Single Dose of Psilocybin
NCT04919850	Not specified	COMPLETED	Effect of 60-days Saccharomyces Boulardii and Superoxide Dismutase Supplementation in Obese Adults
NCT05215431	Not specified	UNKNOWN	Periodontal Health Status in Patients with Systemic Sclerosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).